Meningococcal disease (invasive) surveillance case definition - V1.4

This document contains the case definitions for meningococcal disease (invasive) which is nationally notifiable within Australia. This definition should be used to determine whether a case should be notified.

Page last updated: 19 January 2010

Printable PDF version of Meningococcal disease (invasive) surveillance case definition (PDF 14 KB)

V1.4

Version
Status
Last reviewed
Endorsement date
Implementation date
1.4 Re-examined differences between Meningococcal Guidelines October 2007 case definition and the surveillance case definition and adopted the Guidelines version. CDNA 30 September 2009 CDNA 30 September 2009 1 July 2010
1.3 No Change CDWG 14 August 2008 CDWG 14 August 2008  

1.2

Under Laboratory suggestive evidence delete following text “Positive polysaccharide antigen test in cerebrospinal fluid with other laboratory parameters consistent with meningitis.”

Under Laboratory definitive evidence, add text in bold and italics “Detection of specific meningococcal DNA sequences in a specimen from a normally sterile site by nucleic acid amplification testing.”

Move ‘detection of meningococcus in a specimen from a normally sterile site by nucleic acid testing’ from laboratory suggestive evidence to laboratory definitive evidence.

April 2007

October 2007

 

1.1 Inclusion of PCR testing in laboratory definitive evidence. June 2005 April 2007  
1.0 Initial CDNA case definition (2004)      

Reporting

Both confirmed cases and probable cases should be notified.

Confirmed case

A confirmed case requires either:

1.    Laboratory definitive evidence

OR

2.    Laboratory suggestive evidence AND clinical evidence.

Laboratory definitive evidence

1. Isolation of Neisseria meningitidis from a normally sterile site

OR

2. Detection of specific meningococcal DNA sequences in a specimen from a normally sterile site by nucleic acid amplification testing.

Laboratory suggestive evidence

1. Detection of Gram-negative diplococci in Gram stain of specimen from a normally sterile site or from a suspicious skin lesion

OR

2. High titre IgM or significant rise in IgM or IgG titres to outer membrane protein antigens of N. meningitidis

Clinical evidence (for a confirmed case)

Disease which in the opinion of the treating clinician is compatible with invasive meningococcal disease.

Probable case

A probable case requires clinical evidence only.

Clinical evidence (for a probable case)

A probable case requires:

1.    The absence of evidence for other causes of clinical symptoms

AND EITHER

2.    Clinically compatible disease including haemorrhagic rash

OR

3.    Clinically compatible disease AND close contact with a confirmed case within the previous 60 days.

In this section